Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and Major Osteoporotic Fractures

Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and... Key PointsQuestionDoes the use of topical corticosteroids cause systemic adverse events such as those seen with use of systemic corticosteroids? FindingsIn a cohort study of 723 251 users of potent or very potent topical corticosteroids, use of these drugs was associated with increased risk of osteoporosis and major osteoporotic fracture with a dose-response association for cumulative use. MeaningBased on these findings, clinicians may need to consider other corticosteroid-sparing therapeutic options for people requiring potent anti-inflammatory treatment on large body surfaces for prolonged periods to limit the risk of osteoporosis. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and Major Osteoporotic Fractures

Loading next page...
 
/lp/american-medical-association/association-of-potent-and-very-potent-topical-corticosteroids-and-the-I5YYeNdnUh
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2020.4968
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionDoes the use of topical corticosteroids cause systemic adverse events such as those seen with use of systemic corticosteroids? FindingsIn a cohort study of 723 251 users of potent or very potent topical corticosteroids, use of these drugs was associated with increased risk of osteoporosis and major osteoporotic fracture with a dose-response association for cumulative use. MeaningBased on these findings, clinicians may need to consider other corticosteroid-sparing therapeutic options for people requiring potent anti-inflammatory treatment on large body surfaces for prolonged periods to limit the risk of osteoporosis.

Journal

JAMA DermatologyAmerican Medical Association

Published: Mar 20, 2021

References